



T: 617.573.4865
F: 617.305.4865
john.alessi@skadden.com

Education

J.D., Columbia Law School, 2003
B.A., Duke University, 1996

Bar Admissions

Massachusetts
New York

John Alessi concentrates his practice in the areas of mergers and acquisitions, private equity, public and private financings, securities law and general corporate matters. Mr. Alessi has represented strategic buyers and sellers and private equity sponsors and their portfolio companies in a number of significant transactions, including public and private acquisitions and divestitures, spin-offs, Reverse Morris Trust transactions, proxy contests, debt and equity offerings, joint ventures and other transactional matters. He also has significant experience working in the technology and life sciences sectors.

Mr. Alessi's representations include:

- Biogen, Inc. in its spin-off of Bioerativ Inc., with an initial market capitalization of approximately \$4.8 billion;
- Citrix Systems, Inc. in its spin-off and sale of its "GoTo" software business to LogMeIn, Inc., valued at approximately \$1.8 billion;
- IntraLinks Holdings, Inc. in its auction and sale process resulting in a sale to Synchronoss Technologies, Inc., valued at approximately \$821 million;
- Novell, Inc. in responding to an unsolicited acquisition offer in a process that resulted in an auction and sale of the company in a concurrent patent sale and merger valued at \$2.2 billion;
- Gilead Sciences, Inc. in its acquisition of clinical program asset from a German private biopharmaceutical company in a transaction worth up to \$470 million;
- Broadcom Corporation in its \$165 million acquisition of a modem-related division of Japanese semiconductor manufacturer Renesas Electronics;
- Esselte in the sale to R.R. Donnelley & Sons Company of its North American operations valued at \$100 million;
- Rhythmia Medical, Inc. in its \$265 million sale to Boston Scientific Corporation;
- Broadcom Corporation in its \$3.7 billion acquisition of NetLogic Microsystems Inc.;
- Praecis Pharmaceuticals Incorporated in its sale and licensing of assets to U.K.-based Speciality European Pharma Limited;
- Spectrum Brands, Inc. in a recapitalization of approximately \$800 million in subordinated indebtedness through a negotiated Chapter 11 bankruptcy restructuring;
- Select Income REIT in its initial public offering;
- The RMR Group, Inc. in its public offering by way of a distribution through its public shareholders;
- Paradigm, Ltd. in its \$1 billion sale to Apax Partners and JMI Equity; and
- Acopia Networks in its sale to F5 Networks, Inc. for \$210 million.

In addition to transactional matters, Mr. Alessi regularly advises on a broad range of general corporate matters, including with respect to director duties, shareholder activism defense and disclosure issues under the federal securities laws.

Mr. Alessi is also active in providing *pro bono* services to the community. He has represented individuals in immigration matters through volunteer affiliations with Sanctuary for Families and Kids In Need of Defense as well as nonprofit organizations with respect to their formation and governance structures. Additionally, Mr. Alessi serves as vice-chair of the board of directors for the Massachusetts Appleseed Center for Law and Justice.